{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2010"],"condition":["unresectable advanced/recurrent small intestinal cancer"],"disease":["Unresectable Advanced/recurrent Small Intestinal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2618269"],"location":["Japan"],"study_start_month":["3"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Phase II study of the combination of Oxaliplatin and 5FU(mFOLFOX6) in patients with unresectable advanced/recurrent small intestinal cancer","description":"Interventions: mFOLFOX6\nPrimary outcome(s): Progression-Free rate\nStudy Design: Single arm Non-randomized","dates":{"creation":"2010-03-15"},"accession":"2618269","cross_references":{"Japan Primary Registries Network":["JPRN-UMIN000002797"]}}